Columbus, United States
Visiox Pharmaceuticals, founded in 2022, is a dynamic entity in the biopharma sector, specifically targeting advancements in ophthalmics. With its slogan, "Advancing the Standard of Care in Ophthalmics," the company aims to disrupt and improve current market offerings through innovative therapeutic solutions.
The company's spotlight is on developing and commercializing ophthalmic therapies that meet the market's unmet needs. Their key assets include PDP-716, a once-daily formulation of brimonidine targeting ocular hypertension and open-angle glaucoma, and SDN-037, a twice-daily topical difluprednate aimed at managing post-surgical inflammation and pain. Both therapies leverage a proprietary extended-release technology, securing patent protection until at least 2036.
Headquartered in the United States, Visiox Pharmaceuticals strives to collaborate deeply with eye care professionals, presenting itself as an opportunistic venture for investors seeking to engage with a forward-thinking company committed to significant market influence in the ophthalmic field.
